← Leaderboards
E. Antonio Chiocca
Massachusetts General Hospital
$34,514,665
Attributed
$36,001,367
Total exposure
31
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$89,242,614 · 35
By mechanism
P01$64,034,755 · 18
R01$13,970,587 · 7
U01$9,792,338 · 2
R21$1,111,946 · 4
R25$172,672 · 1
R41$99,875 · 1
Top collaborators
- Michael A Caligiuri11 shared
- Xandra Owens Breakefield9 shared
- Hiroshi Nakashima7 shared
- David Reardon5 shared
- Jianhua Yu1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Mathias Lichterfeld$34,368,889
- Douglas Kwon$11,694,140
- Ahmed A Tawakol$9,912,063
- Steven Kyle Grinspoon$75,757,679
- Markella V. Zanni$10,033,281
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsClinical TrialsGlioblastomaMalignant GliomaResponseMouse ModelGliomaProgramsMalignant NeoplasmsOncolytic VirusesDesignNeoplastic CellImmuneBaseOncolyticMediatingResearch PersonnelImmunotherapySignal TransductionImmune ResponseFutureT-LymphocyteViral
Grant awards (143)
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,654,855
P01 · FY2025 · CA · contact PI
Improving IL12 Immunogene Therapy for Glioblastoma Based on Human Clinical Trial Results$633,656
R01 · FY2025 · NS · contact PI
Oncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune Microenvironment$412,964
R01 · FY2025 · NS · contact PI
Project 2: Analyses of the human GBM microenvironment form clinical trial specimens treated with the oncolytic HSV, rQNestin34v.2$365,084
P01 · FY2025 · CA · contact PI
Core A - Administrative Core$63,709
P01 · FY2025 · CA · contact PI
Understanding and Overcoming T cell Immunosuppression in Glioblastoma$2,680,832
P01 · FY2024 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,599,000
P01 · FY2024 · CA · contact PI
Improving IL12 Immunogene Therapy for Glioblastoma Based on Human Clinical Trial Results$633,656
R01 · FY2024 · NS · contact PI
Proj. 2: Combining immune checkpoint blockade with T cell activation$460,878
P01 · FY2024 · CA · contact PI
Oncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune Microenvironment$458,847
R01 · FY2024 · NS · contact PI
Project 2: Analyses of the human GBM microenvironment form clinical trial specimens treated with the oncolytic HSV, rQNestin34v.2$369,876
P01 · FY2024 · CA · contact PI
Core 3: Mouse GBM models and Imaging Core$239,939
P01 · FY2024 · CA · contact PI
Administrative Core$167,231
P01 · FY2024 · CA · contact PI
Core A - Administrative Core$60,523
P01 · FY2024 · CA · contact PI
Understanding and Overcoming T cell Immunosuppression in Glioblastoma$2,810,976
P01 · FY2023 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,883,308
P01 · FY2023 · CA · contact PI
Proj. 2: Combining immune checkpoint blockade with T cell activation$475,430
P01 · FY2023 · CA · contact PI
Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment$412,687
R01 · FY2023 · NS · contact PI
Project 2: Analyses of the human GBM microenvironment form clinical trial specimens treated with the oncolytic HSV, rQNestin34v.2$400,081
P01 · FY2023 · CA · contact PI
Core 3: Mouse GBM models and Imaging Core$247,517
P01 · FY2023 · CA · contact PI
Administrative Core$172,512
P01 · FY2023 · CA · contact PI
Core A - Administrative Core$83,459
P01 · FY2023 · CA · contact PI
Understanding and Overcoming T cell Immunosuppression in Glioblastoma$2,801,934
P01 · FY2022 · CA · contact PI
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas$1,766,381
P01 · FY2022 · CA · contact PI
Proj. 2: Combining immune checkpoint blockade with T cell activation$475,430
P01 · FY2022 · CA · contact PI
Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment$412,687
R01 · FY2022 · NS · contact PI
Project 2: Clinical evaluation of a novel oHSV in recurrent human GBM$332,873
P01 · FY2022 · CA · contact PI
Core 3: Mouse GBM models and Imaging Core$247,517
P01 · FY2022 · CA · contact PI
Administrative Core$172,512
P01 · FY2022 · CA · contact PI
Core A - Administrative Core$71,295
P01 · FY2022 · CA · contact PI
Understanding and Overcoming T cell Immunosuppression in Glioblastoma$2,832,522
P01 · FY2021 · CA · contact PI
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas$1,789,540
P01 · FY2021 · CA · contact PI
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas$1,316,194
P01 · FY2021 · CA
Proj. 2: Combining immune checkpoint blockade with T cell activation$485,132
P01 · FY2021 · CA · contact PI
Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment$412,687
R01 · FY2021 · NS · contact PI
Project 2: Clinical evaluation of a novel oHSV in recurrent human GBM$339,666
P01 · FY2021 · CA · contact PI
Project 3 Gene Mediated Cytotoxic Immmunotherapy for GBM$290,642
P01 · FY2021 · CA · contact PI
Core 3: Mouse GBM models and Imaging Core$252,569
P01 · FY2021 · CA · contact PI
Administrative Core$176,033
P01 · FY2021 · CA · contact PI
Core A - Administrative Core$72,751
P01 · FY2021 · CA · contact PI
Understanding and Overcoming T cell Immunosuppression in Glioblastoma$3,024,895
P01 · FY2020 · CA · contact PI
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas$1,777,058
P01 · FY2020 · CA · contact PI
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas$1,316,276
P01 · FY2020 · CA
Proj. 2: Combining immune checkpoint blockade with T cell activation$524,632
P01 · FY2020 · CA · contact PI
Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment$416,647
R01 · FY2020 · NS · contact PI
Project 2: Clinical evaluation of a novel oHSV in recurrent human GBM$339,666
P01 · FY2020 · CA · contact PI
Project 3 Gene Mediated Cytotoxic Immmunotherapy for GBM$290,642
P01 · FY2020 · CA · contact PI
Core 3: Mouse GBM models and Imaging Core$247,440
P01 · FY2020 · CA · contact PI
Administrative Core$195,783
P01 · FY2020 · CA · contact PI
Core A - Administrative Core$72,751
P01 · FY2020 · CA · contact PI
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas$1,717,653
P01 · FY2019 · CA · contact PI
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas$1,277,211
P01 · FY2019 · CA
Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment$446,886
R01 · FY2019 · NS · contact PI
Investigating the cytomegalovirus link to glioblastoma using a novel mouse model$366,140
R01 · FY2019 · CA · contact PI
Project 3 Gene Mediated Cytotoxic Immmunotherapy for GBM$330,611
P01 · FY2019 · CA · contact PI
Project 2: Clinical evaluation of a novel oHSV in recurrent human GBM$329,476
P01 · FY2019 · CA · contact PI
Core A - Administrative Core$76,300
P01 · FY2019 · CA · contact PI
Circumventing barriers to effective oncolytic virotherapy of malignant gliomas$1,905,452
P01 · FY2018 · CA · contact PI
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas$1,316,832
P01 · FY2018 · CA
Investigating the cytomegalovirus link to glioblastoma using a novel mouse model$377,464
R01 · FY2018 · CA · contact PI
Project 2: Clinical evaluation of a novel oHSV in recurrent human GBM$339,665
P01 · FY2018 · CA · contact PI
Project 3 Gene Mediated Cytotoxic Immmunotherapy for GBM$290,642
P01 · FY2018 · CA · contact PI
Core A - Administrative Core$92,502
P01 · FY2018 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,693,572
P01 · FY2017 · CA
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas$1,387,951
P01 · FY2017 · CA
Investigating the cytomegalovirus link to glioblastoma using a novel mouse model$377,464
R01 · FY2017 · CA · contact PI
Intracellular Host Tumor Responses to oHSVs and Avenues to Overcome These$374,452
P01 · FY2017 · CA · contact PI
Indirubins: novel anti-invasive and anti-angiogenic drugs for malignant gliomas$368,313
R01 · FY2017 · CA · contact PI
Project 3 Gene Mediated Cytotoxic Immmunotherapy for GBM$308,393
P01 · FY2017 · CA · contact PI
Administration and Biostatistics Core$125,783
P01 · FY2017 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,682,938
P01 · FY2016 · CA
Experimental Therapeutics and BioMonitoring for Brain Tumors$1,348,678
P01 · FY2016 · CA
Investigating the cytomegalovirus link to glioblastoma using a novel mouse model$377,464
R01 · FY2016 · CA · contact PI
Intracellular Host Tumor Responses to oHSVs and Avenues to Overcome These$373,931
P01 · FY2016 · CA · contact PI
Indirubins: novel anti-invasive and anti-angiogenic drugs for malignant gliomas$368,313
R01 · FY2016 · CA · contact PI
The role of microvesicles in giloma virotherapy$323,791
P01 · FY2016 · CA · contact PI
Administration and Biostatistics Core$124,987
P01 · FY2016 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,655,598
P01 · FY2015 · CA
Experimental Therapeutics and BioMonitoring for Brain Tumors$1,332,561
P01 · FY2015 · CA
Investigating the cytomegalovirus link to glioblastoma using a novel mouse model$396,329
R01 · FY2015 · CA · contact PI
Intracellular Host Tumor Responses to oHSVs and Avenues to Overcome These$370,514
P01 · FY2015 · CA · contact PI
Indirubins: novel anti-invasive and anti-angiogenic drugs for malignant gliomas$367,707
R01 · FY2015 · CA · contact PI
The role of microvesicles in giloma virotherapy$324,975
P01 · FY2015 · CA · contact PI
Administration and Biostatistics Core$121,629
P01 · FY2015 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$105,672
P01 · FY2015 · CA
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,612,546
P01 · FY2014 · CA
Experimental Therapeutics and BioMonitoring for Brain Tumors$1,297,716
P01 · FY2014 · CA
Intracellular Host Tumor Responses to oHSVs and Avenues to Overcome These$360,760
P01 · FY2014 · CA · contact PI
Indirubins: novel anti-invasive and anti-angiogenic drugs for malignant gliomas$355,670
R01 · FY2014 · CA · contact PI
The role of microvesicles in giloma virotherapy$317,891
P01 · FY2014 · CA · contact PI
Administration and Biostatistics Core$119,740
P01 · FY2014 · CA · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$89,527
P01 · FY2014 · CA
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,721,925
P01 · FY2013 · CA
Experimental Therapeutics and BioMonitoring for Brain Tumors$1,253,475
P01 · FY2013 · CA
Indirubins: novel anti-invasive and anti-angiogenic drugs for malignant gliomas$365,719
R01 · FY2013 · CA · contact PI
Intracellular Host Tumor Responses to oHSVs and Avenues to Overcome These$342,662
P01 · FY2013 · CA · contact PI
The role of microvesicles in giloma virotherapy$305,416
P01 · FY2013 · CA · contact PI
Administration and Biostatistics Core$132,705
P01 · FY2013 · CA · contact PI
Preclinical Toxicity Evaluation of a Potent Oncolytic Virus$1,994,673
U01 · FY2012 · NS · contact PI
Preclinical Toxicity Evaluation of a Potent Oncolytic Virus$1,378,673
U01 · FY2012 · NS · contact PI
The role of microvesicles in giloma virotherapy$338,770
P01 · FY2012 · CA · contact PI
Preclinical Toxicity Evaluation of a Potent Oncolytic Virus$654,893
U01 · FY2011 · NS · contact PI
Preclinical Toxicity Evaluation of a Potent Oncolytic Virus$654,893
U01 · FY2011 · NS · contact PI
Research Education Program for Residents/Fellows in Neurology and Neurosurgery$55,009
R25 · FY2011 · NS · contact PI
Research Education Program for Residents/Fellows in Neurology and Neurosurgery$1
R25 · FY2011 · NS · contact PI
Preclinical Toxicity Evaluation of a Potent Oncolytic Virus$1,447,337
U01 · FY2010 · NS · contact PI
Preclinical Toxicity Evaluation of a Potent Oncolytic Virus$1,447,337
U01 · FY2010 · NS · contact PI
Pharmacologic Enhancement of Viral Oncolysis$400,162
P01 · FY2010 · CA · contact PI
Research Education Program for Residents/Fellows in Neurology and Neurosurgery$56,932
R25 · FY2010 · NS · contact PI
Research Education Program for Residents/Fellows in Neurology and Neurosurgery$1
R25 · FY2010 · NS · contact PI
Preclinical Toxicity Evaluation of a Potent Oncolytic Virus$602,261
U01 · FY2009 · NS · contact PI
Preclinical Toxicity Evaluation of a Potent Oncolytic Virus$602,261
U01 · FY2009 · NS · contact PI
Pharmacologic Enhancement of Viral Oncolysis$404,129
P01 · FY2009 · CA · contact PI
HSV amplicon vectors for neuroscience research$168,750
R21 · FY2009 · MH · contact PI
HSV vector platform for cell-based delivery of oncolytic adenoviruses to gliomas$164,063
R21 · FY2009 · NS · contact PI
Research Education Program for Residents/Fellows in Neurology and Neurosurgery$60,729
R25 · FY2009 · NS · contact PI
Preclinical Toxicity Evaluation of a Potent Oncolytic Virus$505,005
U01 · FY2008 · NS · contact PI
Preclinical Toxicity Evaluation of a Potent Oncolytic Virus$505,005
U01 · FY2008 · NS · contact PI
Pharmacologic Enhancement of Viral Oncolysis$392,403
P01 · FY2008 · CA · contact PI
HSV amplicon vectors for neuroscience research$202,500
R21 · FY2008 · MH · contact PI
HSV vector platform for cell-based delivery of oncolytic adenoviruses to gliomas$196,875
R21 · FY2008 · NS · contact PI
Pharmacologic Enhancement of Viral Oncolysis$388,358
P01 · FY2007 · CA · contact PI
Biology of Tauopathies Studied with HSV Amplicons$273,324
R01 · FY2007 · NS · contact PI
Interdisciplinary Tumor Complexity Modeling$852,051
R01 · FY2006 · CA · contact PI
Biology of Tauopathies Studied with HSV Amplicons$277,728
R01 · FY2006 · NS · contact PI
Pharmacologic Enhancement of Viral Oncolysis$277,457
P01 · FY2006 · CA · contact PI
Imaging Transcriptional Activation of Gliomas$145,987
R21 · FY2006 · CA · contact PI
Interdisciplinary Tumor Complexity Modeling$849,569
R01 · FY2005 · CA
Biology of Tauopathies Studied with HSV Amplicons$296,787
R01 · FY2005 · NS
Imaging Transcriptional Activation of Gliomas$149,500
R21 · FY2005 · CA
Dose Response/Dynamics Ultrasound Mediated BBB Opening$99,875
R41 · FY2005 · NS
Interdisciplinary Tumor Complexity Modeling$626,982
R01 · FY2004 · CA
Interdisciplinary Tumor Complexity Modeling$462,989
R01 · FY2004 · CA
HSV Amplicon Vectors for Cerebral Ischemia$393,538
R01 · FY2004 · NS
PRECLINICAL EVALUATION OF INTRA-ARTERIAL ONCOLYTIC VIRUS IN PRIMATES$35,475
P51 · FY2004 · RR
Interdisciplinary Tumor Complexity Modeling$1,189,243
R01 · FY2003 · CA
HSV Amplicon Vectors for Cerebral Ischemia$393,538
R01 · FY2003 · NS
PRECLINICAL EVALUATION OF INTRA-ARTERIAL ONCOLYTIC VIRUS IN PRIMATES$24,966
P51 · FY2003 · RR
HSV Amplicon Vectors for Cerebral Ischemia$393,538
R01 · FY2002 · NS
PHARMACOLOGIC ENHANCEMENT OF VIRAL ONCOLYSIS$0
P01 · FY2002 · CA
PHARMACOLOGIC ENHANCEMENT OF VIRAL ONCOLYSIS$0
P01 · FY2001 · CA
INTERDISCIPLINARY DEVELOPMENT OF A COMPUTATIONAL TUMOR M$84,271
R21 · FY2000 · CA
PHARMACOLOGIC ENHANCEMENT OF VIRAL ONCOLYSIS$0
P01 · FY2000 · CA